Talphera Inc (FRA:R5XA)
€ 0.657 -0.013 (-1.94%) Market Cap: 11.40 Mil Enterprise Value: 1.64 Mil PE Ratio: 0 PB Ratio: 1.25 GF Score: 34/100

Q3 2023 AcelRx Pharmaceuticals Inc Earnings Call Transcript

Nov 08, 2023 / 09:30PM GMT
Release Date Price: €0.477 (+4.38%)
Operator

Welcome to the AcelRx third quarter 2023 financial results conference call. This call is being webcasted live via the events page of the Investors section of AcelRx's website at www.acelrx.com. This call is property of AcelRx, and any recording, reproduction or transmission of this call without the expressed written consent of AcelRx is strictly prohibited. As a reminder, this webcast is being recorded. You may listen to a replay of this webcast by going to the Investors section of AcelRx's website. And now I would like to turn the call over to Raffi Asadorian, AcelRx's -- AcelRx Pharmaceuticals' Chief Financial Officer.

Raffi Asadorian AcelRx Pharmaceuticals
Inc. - CFO

Thank you for joining us on the call today. This afternoon, we announced our third quarter 2023 financial results and associated business updates in a press release. This press release can be found within the Investors section of our website.

With me today are Vince Angotti, our Chief Executive Officer, and Dr. Pam Palmer,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot